Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Sleep Disordered Breathing, Obesity and Pregnancy Study (SOAP)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified March 2014 by University of Pittsburgh
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Francesca Facco, MD, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT02086448
First received: February 18, 2014
Last updated: March 11, 2014
Last verified: March 2014
  Purpose

The purpose of this study is to better understand how sleep apnea, a common sleep disorder in which a person has one or more pauses in breathing or shallow breaths while sleeping, may affect pregnancy and to determine the effect of Continuous Positive Airway Pressure (CPAP), a treatment that uses mild air pressure to keep the airways open during sleep, for pregnant women with sleep apnea.


Condition Intervention
Obese
Pregnancy
Sleep Disordered Breathing
Device: CPAP
Device: sham-CPAP

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Sleep Disordered Breathing, Obesity and Pregnancy Study (SOAP)

Resource links provided by NLM:


Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • Uterine artery Doppler mean pulsatility index -by ultrasound [ Time Frame: early pregnancy (14-16 weeks gestation) ] [ Designated as safety issue: No ]
  • sFLT/PIGF ratio-blood measurement [ Time Frame: early pregnancy (14-16 weeks gestation) ] [ Designated as safety issue: No ]
  • Homeostasis model assessment of insulin resistance (HOMA-IR)-blood measurement of glucose and insulin [ Time Frame: early pregnancy (14-16 weeks gestation) ] [ Designated as safety issue: No ]
  • Uterine artery Doppler mean pulsatility index -by ultrasound [ Time Frame: late pregnancy (28-32 weeks gestation) ] [ Designated as safety issue: Yes ]
  • sFLT/PIGF ratio-blood measurement [ Time Frame: late pregnancy (28-32 weeks gestation) ] [ Designated as safety issue: No ]
  • Homeostasis model assessment of insulin resistance (HOMA-IR)-blood measurement of glucose and insulin [ Time Frame: late pregnancy (28-32 weeks gestation) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • placental histology and immunohistochemistry [ Time Frame: After delivery (expected 37-40 weeks gestation) ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • Mean arterial blood pressure (mmHg) Angiogenic Domain [ Time Frame: early pregnancy (14-16 weeks gestation) ] [ Designated as safety issue: No ]
  • Pregnancy outcome data [ Time Frame: At time of delivery (expected 37-40 weeks gestation) ] [ Designated as safety issue: No ]
    Preeclampsia, Gestational diabetes, Gestational age at delivery, Indication for delivery, Birthweight, Cord gases

  • Mean arterial blood pressure (mmHg) Angiogenic Domain [ Time Frame: late pregnancy (28-32 weeks gestation) ] [ Designated as safety issue: No ]
  • sEng (pg/mL)-blood measurement [ Time Frame: early pregnancy (14-16 weeks gestation) ] [ Designated as safety issue: No ]
  • sEng (pg/mL)-blood measurement [ Time Frame: late pregnancy (28-32 weeks gestation) ] [ Designated as safety issue: No ]

Estimated Enrollment: 16
Study Start Date: April 2014
Estimated Study Completion Date: October 2016
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Obese, SDB negative
No intervention
Active Comparator: Obese, SDB postive, CPAP
Therapeutic CPAP
Device: CPAP
CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevents apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
Other Name: Continuous Positive Airway Pressure
Sham Comparator: Obese, SDB postive, sham-CPAP
Sham (non-therapeutic) CPAP
Device: sham-CPAP

Detailed Description:

Emerging data support a link between sleep disordered breathing (SDB) and adverse pregnancy outcomes, particularly preeclampsia. Furthermore, SDB, which is characterized by intermittent nocturnal hypoxia-reoxygenation as well as sleep disruption, results in endothelial dysfunction and metabolic dysregulation, the same biological pathways that have been associated with adverse pregnancy outcomes. Obesity is a well-known risk factor for both adverse pregnancy outcomes and SDB, and has been associated with the same aforementioned biological aberrations. Therefore, obesity complicates the definition of a causal relationship between SDB and pregnancy outcomes. While some classic cardiovascular risk factors (prehypertension) are certainly relevant in pregnancy, there are also well-established risk factors that are unique to pregnancy (uterine vascular stiffness, placental angiogenic factors). The interplay between SDB, obesity and these unique cardiovascular risk factors remains undefined, and this proposal aims to address this knowledge gap. Without this data, our ability to understand how we can mitigate these risks through the use of therapeutic interventions for SDB, such as CPAP (continuous positive airway pressure), is compromised. To further address this knowledge gap, we will make use of the placenta's ability to accumulate evidence of damage over time and provide a record of maternal vascular health throughout gestation. Numerous placental lesions deriving from maternal vascular disease have been identified and can be readily detected on placental pathology. These lesions can provide a measure of the severity of hypoxic stress experienced by the fetus during gestation.

The investigators' central hypothesis is that SDB is an effect modifier that increases maternal cardiovascular risk and placental hypoxic injury in obese pregnant women, and that CPAP treatment during pregnancy will result in an improved cardiovascular risk and placental profile. To test this hypothesis the investigaotrs will identify a cohort of obese women both with and without SDB. The investigators will examine SDB's impact on maternal vascular stiffness (uterine artery Doppler), angiogenesis (pregnancy specific angiogenic factors e.g., sFLT-1) and metabolism (insulin resistance) across pregnancy (Aim 1). The investigators will perform a randomized controlled trial of autotitrating- CPAP verses sham-CPAP in pregnancy to examine the impact of CPAP treatment during pregnancy on cardiovascular risk (Aim 2) and will explore the interplay between SDB, CPAP and evidence of maternal vascular disease and chronic fetal hypoxia by evaluating the placental profile of obese women with and without SDB (Aim 3).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • women between 14 0/7 and 16 6/7 weeks gestation at the time of their initial PSG assessment.
  • Pregnancy and current BMI >=30
  • Self-reported frequent snoring (>=3x/week over past month) or self-reported non-snorer.

Exclusion Criteria:

  • diagnosis of chronic hypertension and pregestational diabetes.
  • self-report a history of sleep apena and who are using or were receommended by a physican to use a PAP device already
  • other significant sleep disorders
  • restless legs syndrome
  • clinically significant insomnia
  • sleeping on average < 6 hours or > 10 hours per night over the previous month
  • self-report taking a sleeping aid > 1 time per month,
  • hypersomnia diagnosis currently treated with stimulant medication
  • history of SDB or treatment with CPAP
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02086448

Contacts
Contact: Francesca Facco, MD 412-641-5406 faccof@upmc.ed

Locations
United States, Pennsylvania
Magee-Womens Hospital of the UPMC
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Investigators
Principal Investigator: Francesca Facco, MD University of Pittsburgh
  More Information

No publications provided

Responsible Party: Francesca Facco, MD, Principal Investigator, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT02086448     History of Changes
Other Study ID Numbers: PRO13080159, K12HD043441
Study First Received: February 18, 2014
Last Updated: March 11, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Respiratory Aspiration
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on November 25, 2014